Microparticle immunocapture assay for quantitation of protein multimer amount and size.

Michael F Gutknecht, Hiroaki Kaku, Thomas L Rothstein

Cell reports methods 2022 May 23

filter terms:

Cellular stress and toxicity are often associated with the formation of protein multimers, or aggregates. Numerous degenerative disorders, including Alzheimer's, Parkinson's, and Huntington's disease, prion-propagated disease, amyotrophic lateral sclerosis, cardiac amyloidosis, and diabetes, are characterized by aggregated protein deposits. Current methods are limited in the ability to assess multimer size along with multimer quantitation and to incorporate one or more ancillary traits, including target specificity, operative simplicity, and process speed. Here, we report development of a microparticle immunocapture assay that combines the advantages inherent to a monoclonal antibody:protein interaction with highly quantitative flow cytometry analysis. Using established reagents to build our platform, and aggregation-prone amyloid beta 1-42 peptide (Aβ42) and alpha-synuclein to demonstrate proof of principle, our results indicate that this assay is a highly adaptable method to measure multimer size and quantity at the same time in a technically streamlined workflow applicable to laboratory and clinical samples. © 2022 The Authors.

Citation

Michael F Gutknecht, Hiroaki Kaku, Thomas L Rothstein. Microparticle immunocapture assay for quantitation of protein multimer amount and size. Cell reports methods. 2022 May 23;2(5):100214